CN101594909A - 用于治疗炎性病症、细胞增殖性失调、免疫失调的irak调节剂 - Google Patents

用于治疗炎性病症、细胞增殖性失调、免疫失调的irak调节剂 Download PDF

Info

Publication number
CN101594909A
CN101594909A CNA2007800414293A CN200780041429A CN101594909A CN 101594909 A CN101594909 A CN 101594909A CN A2007800414293 A CNA2007800414293 A CN A2007800414293A CN 200780041429 A CN200780041429 A CN 200780041429A CN 101594909 A CN101594909 A CN 101594909A
Authority
CN
China
Prior art keywords
imidazo
pyridazin
pyran
tetrahydro
amine
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CNA2007800414293A
Other languages
English (en)
Chinese (zh)
Inventor
托马斯·杜兰德-雷维尔
查尔斯·朱厄尔
查尔斯·哈蒙德
多诺万·钦
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Biogen MA Inc
Original Assignee
Biogen Idec MA Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biogen Idec MA Inc filed Critical Biogen Idec MA Inc
Publication of CN101594909A publication Critical patent/CN101594909A/zh
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/5025—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Diabetes (AREA)
  • Cardiology (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Immunology (AREA)
  • Communicable Diseases (AREA)
  • Hospice & Palliative Care (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Psychology (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Obesity (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Dermatology (AREA)
  • Hematology (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
CNA2007800414293A 2006-09-07 2007-09-07 用于治疗炎性病症、细胞增殖性失调、免疫失调的irak调节剂 Pending CN101594909A (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US84280006P 2006-09-07 2006-09-07
US60/842,800 2006-09-07

Publications (1)

Publication Number Publication Date
CN101594909A true CN101594909A (zh) 2009-12-02

Family

ID=38954611

Family Applications (1)

Application Number Title Priority Date Filing Date
CNA2007800414293A Pending CN101594909A (zh) 2006-09-07 2007-09-07 用于治疗炎性病症、细胞增殖性失调、免疫失调的irak调节剂

Country Status (7)

Country Link
US (1) US20110021513A1 (enExample)
EP (1) EP2063962A2 (enExample)
JP (1) JP2010502716A (enExample)
CN (1) CN101594909A (enExample)
AU (1) AU2007292924A1 (enExample)
CA (1) CA2663091A1 (enExample)
WO (1) WO2008030579A2 (enExample)

Cited By (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103814029A (zh) * 2011-09-23 2014-05-21 拜耳知识产权有限责任公司 取代的咪唑并哒嗪
CN103958515A (zh) * 2011-09-06 2014-07-30 拜耳知识产权有限责任公司 氨基取代的咪唑并哒嗪
CN104114559A (zh) * 2011-12-12 2014-10-22 拜耳知识产权有限责任公司 氨基取代的咪唑并哒嗪
CN104159896A (zh) * 2012-01-13 2014-11-19 百时美施贵宝公司 用作激酶抑制剂的杂环取代的吡啶基化合物
CN104321326A (zh) * 2012-04-04 2015-01-28 拜耳医药股份有限公司 氨基取代的咪唑并哒嗪
CN104470523A (zh) * 2012-03-09 2015-03-25 莱西肯医药有限公司 基于咪唑并[1,2-b]哒嗪的化合物、包含它们的组合物及其使用方法
CN104592121A (zh) * 2015-02-13 2015-05-06 佛山市赛维斯医药科技有限公司 含酰肼和硝基苯类结构的化合物、其制备方法及用途
CN105517552A (zh) * 2013-09-06 2016-04-20 莱西肯医药有限公司 基于咪唑并[1,2-b]哒嗪的化合物、包含它们的组合物及其使用方法
CN106458982A (zh) * 2014-01-10 2017-02-22 奥列基因发现技术有限公司 作为irak4抑制剂的吲唑化合物
CN108026099A (zh) * 2015-06-24 2018-05-11 百时美施贵宝公司 经杂芳基取代的氨基吡啶化合物
CN110785418A (zh) * 2017-06-21 2020-02-11 豪夫迈·罗氏有限公司 作为irak4调节剂的异二氢吲哚酮衍生物
CN111226956A (zh) * 2019-11-26 2020-06-05 贵州医科大学 3,6-二取代咪唑[1,2-b]哒嗪类衍生物在制备杀菌剂中的应用
WO2022166860A1 (zh) * 2021-02-08 2022-08-11 杭州邦顺制药有限公司 Pim激酶抑制剂

Families Citing this family (73)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101600718B (zh) * 2006-11-06 2013-07-03 特雷罗药物股份有限公司 咪唑并[1,2-b]哒嗪和吡唑并[1,5-a]嘧啶衍生物及其作为蛋白激酶抑制剂的用途
AR067326A1 (es) * 2007-05-11 2009-10-07 Novartis Ag Imidazopiridinas y pirrolo -pirimidinas sustituidas como inhibidores de cinasa de lipido
ES2400604T3 (es) * 2007-08-17 2013-04-11 Icagen, Inc. Heterociclos como moduladores del canal de potasio
US8431608B2 (en) 2007-08-17 2013-04-30 Icagen Inc. Heterocycles as potassium channel modulators
WO2009106577A1 (en) 2008-02-28 2009-09-03 Novartis Ag Imidazo [1,2-b] pyridazine derivatives for the treatment of c-met tyrosine kinase mediated disease
JPWO2009128520A1 (ja) * 2008-04-18 2011-08-04 塩野義製薬株式会社 Ｐｉ３ｋ阻害活性を有する複素環化合物
US20110071052A1 (en) * 2008-04-25 2011-03-24 Maria Helena Hilhorst Measurement of protein kinase activity in cerebrospinal fluid for diagnosis of neurological and psychiatric disorders
EP2300469B1 (en) * 2008-05-13 2015-06-24 Novartis AG Fused nitrogen containing heterocycles and compositions thereof as kinase inhibitors
UY32049A (es) 2008-08-14 2010-03-26 Takeda Pharmaceutical Inhibidores de cmet
RS53350B (sr) 2008-09-22 2014-10-31 Array Biopharma, Inc. Supstituisana jedinjenja imidazo[1,2-b]piridazina kao inhibitori trk kinaze
TWI491610B (zh) 2008-10-09 2015-07-11 必治妥美雅史谷比公司 作為激酶抑制劑之咪唑并嗒腈
PT2725028T (pt) 2008-10-22 2016-08-31 Array Biopharma Inc Compostos de pirazolo[1,5-]pirimidina substituídos como intermediários na síntese de inibidores de cinase trk
WO2010062829A1 (en) * 2008-11-28 2010-06-03 Lexicon Pharmaceuticals, Inc. Tryptophan hydroxylase inhibitors for treating osteoporosis
PA8851101A1 (es) 2008-12-16 2010-07-27 Lilly Co Eli Compuesto amino pirazol
CN102388055B (zh) * 2009-04-02 2015-07-29 卡洛斯三世国家癌症研究中心基金会 咪唑并[2,1-b][1,3,4]噻二唑衍生物
EP2243481A1 (en) * 2009-04-24 2010-10-27 PamGene B.V. Irak kinase family as novel drug target for Alzheimer
AR077468A1 (es) 2009-07-09 2011-08-31 Array Biopharma Inc Compuestos de pirazolo (1,5 -a) pirimidina sustituidos como inhibidores de trk- quinasa
US8389526B2 (en) 2009-08-07 2013-03-05 Novartis Ag 3-heteroarylmethyl-imidazo[1,2-b]pyridazin-6-yl derivatives
EA020847B1 (ru) 2009-10-30 2015-02-27 Янссен Фармацевтика Нв ПРОИЗВОДНЫЕ ИМИДАЗО[1,2-b]ПИРИДАЗИНА И ИХ ПРИМЕНЕНИЕ В КАЧЕСТВЕ ИНГИБИТОРОВ PDE10
AR080754A1 (es) 2010-03-09 2012-05-09 Janssen Pharmaceutica Nv Derivados de imidazo (1,2-a) pirazina y su uso como inhibidores de pde10
WO2011137155A1 (en) 2010-04-28 2011-11-03 Bristol-Myers Squibb Company Imidazopyridazinyl compounds and their uses for cancer
HUE044025T2 (hu) 2010-05-20 2019-09-30 Array Biopharma Inc Makrociklusos vegyületek mint TRK-kináz inhibitorok
US9266880B2 (en) 2010-11-12 2016-02-23 Bristol-Myers Squibb Company Substituted azaindazole compounds
CN103298792A (zh) * 2010-11-19 2013-09-11 利亘制药公司 杂环胺及其用途
EP2463289A1 (en) * 2010-11-26 2012-06-13 Almirall, S.A. Imidazo[1,2-b]pyridazine derivatives as JAK inhibitors
JP6121991B2 (ja) * 2011-05-17 2017-04-26 バイエル・インテレクチュアル・プロパティ・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツングＢａｙｅｒ Ｉｎｔｅｌｌｅｃｔｕａｌ Ｐｒｏｐｅｒｔｙ ＧｍｂＨ Ｍｋｎｋ１キナーゼ阻害剤としてのアミノ置換イミダゾピリダジン
WO2012163942A1 (en) 2011-06-01 2012-12-06 Bayer Intellectual Property Gmbh Substituted aminoimidazopyridazines
EP2723748B1 (en) * 2011-06-22 2016-10-12 Bayer Intellectual Property GmbH Heterocyclyl aminoimidazopyridazines
WO2013000924A1 (en) 2011-06-27 2013-01-03 Janssen Pharmaceutica Nv 1-ARYL-4-METHYL-[1,2,4]TRIAZOLO[4,3-a]QUINOXALINE DERIVATIVES
ES2671748T3 (es) 2011-07-21 2018-06-08 Tolero Pharmaceuticals, Inc. Inhibidores heterocíclicos de proteína quinasas
US8969586B2 (en) 2011-09-27 2015-03-03 Bristol-Myers Squibb Company Substituted bicyclic heteroaryl compounds
EP2773207B1 (en) * 2011-10-31 2018-03-07 Merck Sharp & Dohme Corp. Aminopyrimidinones as interleukin receptor-associated kinase inhibitors
CA2868673A1 (en) * 2012-03-29 2013-10-03 Bayer Intellectual Property Gmbh Amino-substituted imidazopyridazines
EP2863909B1 (en) 2012-06-26 2020-11-04 Janssen Pharmaceutica N.V. Combinations comprising 4-methyl-[1,2,4]triazolo[4,3-a]quinoxaline compounds as pde 2 inhibitors and pde 10 inhibitors for use in the treatment of neurological or metabolic disorders
MX362197B (es) 2012-07-09 2019-01-08 Janssen Pharmaceutica Nv Derivados de imidazo[1,2-b]piridazina e imidazo[1,2-a]pirazina como inhibidores de la fosfodiesterasa 10; y el uso de los mismos en el tratamiento de trastornos neurológicos, psiquiátricos y metabólicos.
PL400213A1 (pl) 2012-08-01 2014-02-03 Celon Pharma Spólka Z Ograniczona Odpowiedzialnoscia Pochodne imidazo[1,2-b]pirydazyno-6-aminy jako inhibitory kinazy JAK-2
KR102229478B1 (ko) 2012-11-01 2021-03-18 인피니티 파마슈티칼스, 인코포레이티드 Pi3 키나아제 동형단백질 조절인자를 사용하는 암의 치료
ES2655030T3 (es) 2012-11-19 2018-02-16 Novartis Ag Compuestos y composiciones para el tratamiento de enfermedades parasitarias
ES2646916T3 (es) 2012-11-19 2017-12-18 Bayer Pharma Aktiengesellschaft Aminoimidazopiridazinas como inhibidores de MKNK1 cinasa
CA2899352A1 (en) 2013-01-30 2014-08-07 Bayer Pharma Aktiengesellschaft Amidoimidazopyridazines as mknk-1 kinase inhibitors
WO2014128093A1 (en) 2013-02-20 2014-08-28 Bayer Pharma Aktiengesellschaft Substituted-imidazo[1,2-b]pyridazines as mknk1 inhibitors
CN105431148A (zh) 2013-03-07 2016-03-23 加利菲亚生物公司 混合谱系激酶抑制剂及治疗方法
US20160024051A1 (en) 2013-03-15 2016-01-28 Infinity Pharmaceuticals, Inc. Salts and solid forms of isoquinolinones and composition comprising and methods of using the same
RU2019134551A (ru) 2013-05-30 2019-11-22 Инфинити Фармасьютикалз, Инк. Лечение злокачественных опухолей с использованием модуляторов изоформ pi3-киназы
ES2702126T3 (es) * 2013-12-10 2019-02-27 Bristol Myers Squibb Co Compuestos de imidazopiridazina útiles como moduladores de respuestas a IL-12, IL-23 y/o IFN alfa
CA2936024A1 (en) * 2014-01-09 2015-07-16 Bayer Pharma Aktiengesellschaft Amido-substituted imidazopyridazines useful in the treatment of hyper-proliferative and/or angiogenesis disorders
NZ722019A (en) * 2014-01-13 2022-07-01 Aurigene Discovery Tech Ltd Bicyclic heterocyclyl derivatives as irak4 inhibitors
US9926330B2 (en) 2014-09-30 2018-03-27 Merck Sharp & Dohme Corp. Inhibitors of IRAK4 activity
US9969749B2 (en) 2014-09-30 2018-05-15 Merck Sharp & Dohme Corp. Inhibitors of IRAK4 activity
EP3200790B1 (en) * 2014-09-30 2020-08-26 Merck Sharp & Dohme Corp. Inhibitors of irak4 activity
WO2016053772A1 (en) * 2014-09-30 2016-04-07 Merck Sharp & Dohme Corp. Inhibitors of irak4 activity
FI3699181T3 (fi) 2014-11-16 2023-03-28 Array Biopharma Inc Kiteinen muoto (s)-n-(5-((r)-2-(2,5-diluorifenyyli)-pyrrolidin-1-yyli)-pyratsolo[1,5-a]pyrimidin-3-yyli)-3-hydroksipyrrolidiini-1-karboksamidivetyysulfaatista
JP6568588B2 (ja) 2014-12-19 2019-08-28 ヤンセン ファーマシューティカ エヌ．ベー． ＰＩ３Ｋβ阻害剤としてのイミダゾピリダジン誘導体
HRP20192162T1 (hr) 2014-12-19 2020-02-21 Janssen Pharmaceutica N.V. Heterociklil vezani derivati imidazopiridazina kao inhibitori pi3kbeta
US10807983B2 (en) 2015-03-16 2020-10-20 Ligand Pharmaceuticals, Inc. Imidazo-fused heterocycles and uses thereof
WO2017004134A1 (en) * 2015-06-29 2017-01-05 Nimbus Iris, Inc. Irak inhibitors and uses thereof
EP3368039A1 (en) 2015-10-26 2018-09-05 The Regents of The University of Colorado, A Body Corporate Point mutations in trk inhibitor-resistant cancer and methods relating to the same
RS65987B1 (sr) 2016-04-04 2024-10-31 Loxo Oncology Inc Tečne formulacije (s)-n-(5-((r)-2-(2,5-difluorofenil)-pirolidin-1-il)-pirazolo[1,5-]pirimidin-3-il)-3-hidroksipirolidin-1-karboksamida
US10045991B2 (en) 2016-04-04 2018-08-14 Loxo Oncology, Inc. Methods of treating pediatric cancers
EP3800189B1 (en) 2016-05-18 2023-06-28 Loxo Oncology, Inc. Preparation of (s)-n-(5-((r)-2-(2,5-difluorophenyl)pyrrolidin-1-yl)pyrazolo[1,5-a]pyrimidin-3-yl)-3-hydroxypyrrolidine-1-carboxamide
US11254667B2 (en) 2016-08-17 2022-02-22 Children's Hospital Medical Center Substituted imidazo[1,2-A]pyridines as IRAK 1/4 and flt3 inhibitors
US11542261B2 (en) 2016-08-17 2023-01-03 Children's Hospital Medical Center Substituted Imidazo[1,2-a]-pyridines as IRAK 1/4 and FLT3 inhibitors
WO2018050286A1 (en) * 2016-09-16 2018-03-22 Helmholtz Zentrum Muenchen - Deutsches Forschungszentrum Für Gesundheit Und Umwelt (Gmbh) Traf 6 inhibitors
JOP20190092A1 (ar) 2016-10-26 2019-04-25 Array Biopharma Inc عملية لتحضير مركبات بيرازولو[1، 5-a]بيريميدين وأملاح منها
US11547696B2 (en) 2016-10-28 2023-01-10 Children's Hospital Medical Center Methods and compositions for treatment of myelodysplastic syndromes and/or acute myeloid leukemias
JOP20190213A1 (ar) 2017-03-16 2019-09-16 Array Biopharma Inc مركبات حلقية ضخمة كمثبطات لكيناز ros1
IL305150B2 (en) 2017-03-31 2025-03-01 Aurigene Oncology Ltd Compounds and preparations for the treatment of hematological disorders
SI3704108T1 (sl) 2017-10-31 2024-07-31 Curis, Inc. Inhibitor irak4 v kombinaciji z inhibitorjem bcl-2 za uporabo pri zdravljenju raka
TWI816742B (zh) * 2018-01-29 2023-10-01 美商維泰克斯製藥公司 Gcn2抑制劑及其用途
CA3127502A1 (en) 2019-02-12 2020-08-20 Sumitomo Dainippon Pharma Oncology, Inc. Formulations comprising heterocyclic protein kinase inhibitors
CA3176337A1 (en) 2020-04-21 2021-10-28 Peter King Rna-binding protein multimerization inhibitors and methods of use thereof
EP4319750A4 (en) 2021-04-08 2025-02-26 Curis, Inc. COMBINATION THERAPIES FOR THE TREATMENT OF CANCER
CR20240080A (es) 2021-08-18 2024-04-09 Gilead Sciences Inc Degradadores bifuncionales de quinasas asociadas al receptor de interleucina 1 y usos terapéuticos de los mismos

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0103926D0 (en) * 2001-02-17 2001-04-04 Astrazeneca Ab Chemical compounds
JP2003137785A (ja) * 2001-08-23 2003-05-14 Takeda Chem Ind Ltd Ｊｎｋ活性化阻害剤
WO2003018020A1 (en) * 2001-08-23 2003-03-06 Takeda Chemical Industries, Ltd. Jnk inhibitors
WO2006070943A1 (ja) * 2004-12-28 2006-07-06 Takeda Pharmaceutical Company Limited 縮合イミダゾール化合物およびその用途
EP1849465A4 (en) * 2005-02-18 2008-12-24 Takeda Pharmaceutical AGENS TO CONTROL THE FUNCTION OF THE GPR34 RECEPTOR
DE102005042742A1 (de) * 2005-09-02 2007-03-08 Schering Ag Substituierte Imidazo[1,2b]pyridazine als Kinase-Inhibitoren, deren Herstellung und Verwendung als Arzneimittel
WO2007034278A2 (en) * 2005-09-19 2007-03-29 Pfizer Products Inc. Fused imidazole derivatives as c3a receptor antagonists
WO2007034282A2 (en) * 2005-09-19 2007-03-29 Pfizer Products Inc. Diaryl-imidazole compounds condensed with a heterocycle as c3a receptor antagonists
CN101600718B (zh) * 2006-11-06 2013-07-03 特雷罗药物股份有限公司 咪唑并[1,2-b]哒嗪和吡唑并[1,5-a]嘧啶衍生物及其作为蛋白激酶抑制剂的用途

Cited By (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103958515A (zh) * 2011-09-06 2014-07-30 拜耳知识产权有限责任公司 氨基取代的咪唑并哒嗪
CN103958515B (zh) * 2011-09-06 2016-11-09 拜耳知识产权有限责任公司 氨基取代的咪唑并哒嗪
CN103814029A (zh) * 2011-09-23 2014-05-21 拜耳知识产权有限责任公司 取代的咪唑并哒嗪
CN103814029B (zh) * 2011-09-23 2016-10-12 拜耳知识产权有限责任公司 取代的咪唑并哒嗪
CN104114559B (zh) * 2011-12-12 2016-08-24 拜耳知识产权有限责任公司 氨基取代的咪唑并哒嗪
CN104114559A (zh) * 2011-12-12 2014-10-22 拜耳知识产权有限责任公司 氨基取代的咪唑并哒嗪
CN104159896B (zh) * 2012-01-13 2017-05-24 百时美施贵宝公司 用作激酶抑制剂的杂环取代的吡啶基化合物
CN104159896A (zh) * 2012-01-13 2014-11-19 百时美施贵宝公司 用作激酶抑制剂的杂环取代的吡啶基化合物
CN104470523A (zh) * 2012-03-09 2015-03-25 莱西肯医药有限公司 基于咪唑并[1,2-b]哒嗪的化合物、包含它们的组合物及其使用方法
CN104470523B (zh) * 2012-03-09 2017-07-11 莱西肯医药有限公司 基于咪唑并[1,2‑b]哒嗪的化合物、包含它们的组合物及其使用方法
CN104321326A (zh) * 2012-04-04 2015-01-28 拜耳医药股份有限公司 氨基取代的咪唑并哒嗪
CN105517552A (zh) * 2013-09-06 2016-04-20 莱西肯医药有限公司 基于咪唑并[1,2-b]哒嗪的化合物、包含它们的组合物及其使用方法
CN106458982A (zh) * 2014-01-10 2017-02-22 奥列基因发现技术有限公司 作为irak4抑制剂的吲唑化合物
CN104592121A (zh) * 2015-02-13 2015-05-06 佛山市赛维斯医药科技有限公司 含酰肼和硝基苯类结构的化合物、其制备方法及用途
CN108026099A (zh) * 2015-06-24 2018-05-11 百时美施贵宝公司 经杂芳基取代的氨基吡啶化合物
CN110785418A (zh) * 2017-06-21 2020-02-11 豪夫迈·罗氏有限公司 作为irak4调节剂的异二氢吲哚酮衍生物
CN111226956A (zh) * 2019-11-26 2020-06-05 贵州医科大学 3,6-二取代咪唑[1,2-b]哒嗪类衍生物在制备杀菌剂中的应用
CN111226956B (zh) * 2019-11-26 2021-10-26 贵州医科大学 3,6-二取代咪唑[1,2-b]哒嗪类衍生物在制备抑制植物病原真菌杀菌剂中的应用
WO2022166860A1 (zh) * 2021-02-08 2022-08-11 杭州邦顺制药有限公司 Pim激酶抑制剂

Also Published As

Publication number Publication date
CA2663091A1 (en) 2008-03-13
WO2008030579A2 (en) 2008-03-13
AU2007292924A1 (en) 2008-03-13
EP2063962A2 (en) 2009-06-03
US20110021513A1 (en) 2011-01-27
WO2008030579A3 (en) 2009-02-26
JP2010502716A (ja) 2010-01-28

Similar Documents

Publication Publication Date Title
CN101594909A (zh) 用于治疗炎性病症、细胞增殖性失调、免疫失调的irak调节剂
CN114748622B (zh) P38激酶抑制剂降低dux4和下游基因表达以用于治疗fshd
CN101547924B (zh) 抑制有丝分裂的化合物
JP2020050682A (ja) ドライアイおよび他の目に関連する疾患を治療するためのヤヌスキナーゼ阻害剤
US10844064B2 (en) sGC stimulators
ES2445917T3 (es) Inhibidores de quinasa 1 reguladora de la señal de apoptosis
KR100913845B1 (ko) 트리아졸로[4,5-ｄ]피리미딘 유도체 및 퓨린작동성 수용체길항제로서의 그의 이용
AU6583300A (en) Imidazo(1,2-a)pyridine and pyrazolo(2,3-a)pyridine derivatives
CN104540834B (zh) 新噻吩并嘧啶衍生物、其制备方法及其治疗用途
CN104910161A (zh) 作为jak抑制剂的吡唑并嘧啶化合物和方法
CN101589043A (zh) 嘌呤衍生物
JP2015536973A (ja) ＰＤＥ４阻害剤とＰＩ３δ阻害剤または二重ＰＩ３δ−γキナーゼ阻害剤とを含有する薬学的組成物
US10537560B2 (en) P38 kinase inhibitors reduce DUX4 and downstream gene expression for the treatment of FSHD
CA2657931A1 (en) 3-aryl-6-aryl-7h-[1,2,4]triazolo[3,4-b][1,3,4]thiadiazines and analogs as activators of caspases and inducers of apoptosis and the use thereof
CN111032630B (zh) 一种化合物，其药物组合物及其用途及应用
CN110382501A (zh) 用于治疗认知损害的苯并二氮杂环庚三烯衍生物，组合物和方法
TW202340212A (zh) 治療性化合物及其使用方法
CN111542529B (zh) 对蛋白激酶具有抑制活性的噻吩并[3,2-d]嘧啶化合物
CN110835336A (zh) 含氧杂环取代唑类化合物及其用途
HK1220975B (zh) 作为选择性jak3和/或jak1激酶抑制剂的芳杂环化合物的制备方法及其应用

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C02 Deemed withdrawal of patent application after publication (patent law 2001)
WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20091202